Ketyalix

Quetiapine, the active ingredient in Ketyalix, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed for the management of schizophrenia, bipolar disorder—including manic and depressive episodes, and as an adjunct treatment for major depressive disorder in adult patients and is used under medical supervision.

GNH USA supplies Ketyalix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global therapeutic needs.

Quetiapine is an atypical antipsychotic that modulates neurotransmitter activity in several psychiatric disorders.

- Schizophrenia: reduces hallucinations, delusions and thought disorder, helping patients regain functional stability. - Bipolar disorder (manic and depressive episodes): stabilises mood swings, decreasing mania severity and alleviating depressive symptoms. - Adjunct treatment of major depressive disorder: enhances antidepressant response when added to standard therapy, improving overall mood and functionality.

Quetiapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain - Dizziness or light‑headedness - Orthostatic hypotension

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Agranulocytosis or severe leukopenia - Tardive dyskinesia or other movement disorders - Suicidal thoughts or behavior - Severe hypotension or cardiac arrhythmia - Myocarditis or pericarditis

Before initiating therapy, clinicians should consider several safety measures.

- Monitor metabolic parameters: regularly assess weight, fasting glucose and lipid profile. - Assess cardiovascular status: check blood pressure and heart rate, especially in patients with orthostatic risk. - Evaluate hepatic and renal function: adjust use if significant impairment is present. - Review psychiatric history: monitor for emergence of suicidal ideation or worsening depression. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Quetiapine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels and toxicity. - CNS depressants (e.g., alcohol, benzodiazepines): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce quetiapine concentrations, diminishing efficacy. - Antihypertensive agents: additive orthostatic hypotension risk. - Anticholinergic drugs: may exacerbate dry mouth and constipation.